Literature DB >> 2191152

Envelope cross-reactivity between human immunodeficiency virus types 1 and 2 detected by different serological methods: correlation between cross-neutralization and reactivity against the main neutralizing site.

B Böttiger1, A Karlsson, P A Andreasson, A Nauclér, C M Costa, E Norrby, G Biberfeld.   

Abstract

A total of 70 human immunodeficiency virus type 1 (HIV-1) and 42 HIV-2 antibody-positive serum samples, collected from groups of individuals in which only one type of HIV prevails, were tested for cross-reactivity against HIV-2 and HIV-1 proteins by Western blot (WB) (immunoblot), radioimmunoprecipitation assay (RIPA), neutralization analysis, and enzyme-linked immunosorbent assay with as antigen synthetic peptides representing selected parts of the envelope (env) glycoproteins. Cross-reactions against the env glycoproteins were observed by WB in 10% (7 of 70) and by RIPA in 40% (28 of 70) of the HIV-1 antibody-positive serum samples and by WB in 29% (12 of 42) and by RIPA in 48% (20 of 42) of the HIV-2 antibody-positive serum samples. Testing by enzyme-linked immunosorbent assay against a 36-amino-acid peptide (Cys-301-Cys-336) of the external glycoprotein of strain HTLV-IIIB of HIV-1 (HIV-1HTLV-IIIB) (known to represent a dominating, linear neutralizing site) showed type-specific reactions in 67% (38 of 57) of HIV-1 antibody-positive serum samples. Type-specific reactions against a homologous 35-amino-acid peptide of strain SBL-6669 of HIV-2 (HIV-2SBL-6669) were found in 75% (30 of 40) of HIV-2 antibody-positive serum samples, and these reactions were correlated to neutralization against HIV-2SBL-6669. Cross-reactions against these peptides were seen in 23% (13 of 57) and 33% (13 of 40) of the HIV-1 and HIV-2 antibody-positive serum samples, respectively. These cross-reactions were correlated to cross-neutralization against HIV-1HTLV-IIIB and HIV-2SBL-6669. Cross-neutralization against one heterotypic virus strain was demonstrated in 16% (9 of 57) of HIV-1 antibody-positive serum samples and in 22% (5 of 22) of HIV-2 antibody-positive serum samples, but no correlation was found between cross-neutralization and env cross-reactivity in WB or RIPA.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2191152      PMCID： PMC249614     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  27 in total

1.  Isolation of a new human retrovirus from West African patients with AIDS.

Authors:  F Clavel; D Guétard; F Brun-Vézinet; S Chamaret; M A Rey; M O Santos-Ferreira; A G Laurent; C Dauguet; C Katlama; C Rouzioux
Journal:  Science       Date:  1986-07-18       Impact factor: 47.728

2.  Discrimination between antibodies to HIV and to related retroviruses using site-directed serology.

Authors:  E Norrby; G Biberfeld; F Chiodi; A von Gegerfeldt; A Nauclér; E Parks; R Lerner
Journal:  Nature       Date:  1987 Sep 17-23       Impact factor: 49.962

3.  New human T-lymphotropic retrovirus related to simian T-lymphotropic virus type III (STLV-IIIAGM).

Authors:  P J Kanki; F Barin; S M'Boup; J S Allan; J L Romet-Lemonne; R Marlink; M F McLane; T H Lee; B Arbeille; F Denis
Journal:  Science       Date:  1986-04-11       Impact factor: 47.728

4.  Antibody to a synthetic oligopeptide in subjects at risk for human immunodeficiency virus infection.

Authors:  R S Smith; R B Naso; J Rosen; A Whalley; Y L Hom; K Hoey; C J Kennedy; J A McCutchan; S A Spector; D D Richman
Journal:  J Clin Microbiol       Date:  1987-08       Impact factor: 5.948

5.  Radioimmunoprecipitation and Western blotting with sera of human immunodeficiency virus infected patients: a comparative study.

Authors:  F Chiodi; U Bredberg-Råden; G Biberfeld; B Böttiger; J Albert; B Asjö; E M Fenyö; E Norrby
Journal:  AIDS Res Hum Retroviruses       Date:  1987       Impact factor: 2.205

6.  Synthetic peptide immunoassay distinguishes HIV type 1 and HIV type 2 infections.

Authors:  J W Gnann; J B McCormick; S Mitchell; J A Nelson; M B Oldstone
Journal:  Science       Date:  1987-09-11       Impact factor: 47.728

Review 7.  AIDS: an international perspective.

Authors:  P Piot; F A Plummer; F S Mhalu; J L Lamboray; J Chin; J M Mann
Journal:  Science       Date:  1988-02-05       Impact factor: 47.728

8.  Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope.

Authors:  S Matsushita; M Robert-Guroff; J Rusche; A Koito; T Hattori; H Hoshino; K Javaherian; K Takatsuki; S Putney
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

9.  Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.

Authors:  T J Palker; M E Clark; A J Langlois; T J Matthews; K J Weinhold; R R Randall; D P Bolognesi; B F Haynes
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

Review 10.  HIV-2, the West African AIDS virus.

Authors:  F Clavel
Journal:  AIDS       Date:  1987-09       Impact factor: 4.177
View more
  18 in total

Review 1.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

2.  Variation in simian immunodeficiency virus env is confined to V1 and V4 during progression to simian AIDS.

Authors:  J Overbaugh; L M Rudensey; M D Papenhausen; R E Benveniste; W R Morton
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

3.  Cloning, expression, and purification of HIV-2 gp125: A target for HIV vaccination.

Authors:  Samer Sourial; Anette Wärnmark; Charlotta Nilsson; Ewa Björling; Adnane Achour; Robert A Harris
Journal:  Mol Biotechnol       Date:  2005-06       Impact factor: 2.695

4.  Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity.

Authors:  E Björling; K Broliden; D Bernardi; G Utter; R Thorstensson; F Chiodi; E Norrby
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

5.  Localization of immunogenic domains in the human immunodeficiency virus type 2 envelope.

Authors:  M L Huang; M Essex; T H Lee
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

6.  Use of a new dual-antigen enzyme-linked immunosorbent assay to detect and characterize the human antibody response to the human immunodeficiency virus type 2 envelope gp125 and gp36 glycoproteins.

Authors:  José Maria Marcelino; Helena Barroso; Fátima Gonçalves; Sofia Marques Silva; Carlos Novo; Perpétua Gomes; Ricardo Camacho; Nuno Taveira
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

7.  High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.

Authors:  Katie L Davis; Elin S Gray; Penny L Moore; Julie M Decker; Aidy Salomon; David C Montefiori; Barney S Graham; Michael C Keefer; Abraham Pinter; Lynn Morris; Beatrice H Hahn; George M Shaw
Journal:  Virology       Date:  2009-03-18       Impact factor: 3.616

8.  Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates.

Authors:  M Robert-Guroff; K Aldrich; R Muldoon; T L Stern; G P Bansal; T J Matthews; P D Markham; R C Gallo; G Franchini
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

9.  Immunological reactivity of a human immunodeficiency virus type I derived peptide representing a consensus sequence of the GP120 major neutralizing region V3.

Authors:  R Wagner; S Modrow; T Böltz; H Fliessbach; M Niedrig; A von Brunn; H Wolf
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

10.  Identification of amino acids in the V3 region of gp120 critical for virus neutralization by human HIV-1-specific antibodies.

Authors:  P A Broliden; B Mäkitalo; L Akerblom; J Rosen; K Broliden; G Utter; M Jondal; E Norrby; B Wahren
Journal:  Immunology       Date:  1991-08       Impact factor: 7.397
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.